AmCad BioMed Corporation (TPEX:4188)

Market Cap	899.33M -34.0%
Revenue (ttm)	43.51M -25.5%
Net Income	-48.44M
EPS	-0.76
Shares Out	63.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,016
Average Volume	45,860
Open	13.80
Previous Close	13.75
Day's Range	13.70 - 14.20
52-Week Range	12.30 - 21.75
Beta	0.36
RSI	47.41
Earnings Date	Feb 26, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 34
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4188

Financial Performance

In 2024, AmCad BioMed's revenue was 53.11 million, a decrease of -18.62% compared to the previous year's 65.26 million. Losses were -50.58 million, 11.6% more than in 2023.